• Oct 8, 2026

USDA opens the door to engineered biologics in poultry

On 29 September 2026, US animal health company BiomEdit announced that the USDA's Center for Veterinary Biologics granted conditional licensure for CPerf LLV, an engineered probiotic strain designed to neutralise the Clostridium perfringens toxins (alpha toxin and NetB) behind necrotic enteritis in broilers.

Key points from the announcement:

• Conditional licensure is based on safety and a "reasonable expectation of efficacy"; full licensure still requires more data.
• BiomEdit reports that its pivotal study, reviewed by USDA CVB, showed necrotic enteritis-associated mortality falling from 13.1% in challenged controls to 6.6% in treated birds.
• The company believes it is the first genetically engineered probiotic biologic licensed for any animal species worldwide.
• Commercial evaluation has started with three major US poultry producers, covering more than 35 million broilers.

Why it matters

Necrotic enteritis is one of the most costly diseases in broiler production, and pressure to reduce antibiotic use is growing in every market we serve. Science has been producing new non-antibiotic tools for years, including engineered probiotics, bacteriophages and targeted antibodies. Very often the bottleneck is not the biology but the regulatory route to market. A national regulator creating a workable, conditional pathway for a genuinely new class of biologic is a significant step. It shows these technologies can be assessed, licensed and put into real production systems while the evidence base keeps growing.

For mills and nutrition teams, the practical message is that the toolkit for gut health without antibiotics is widening. We will keep following how regulators in Europe and the Gulf respond to this new class of products.

Read BiomEdit's full announcement: BiomEdit press release (PR Newswire)